Intensity Therapeutics
INTS
16 hedge funds and large institutions have $2.76M invested in Intensity Therapeutics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
13,391% more capital inflows, than outflows
Capital inflows: $2.33M | Capital outflows: $17.3K
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
17.73% more ownership
Funds ownership: 7.15% → 24.87% (+18%)
14% more funds holding
Funds holding: 14 → 16 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kingsbury Capital Investment Advisors
Wilmette,
Illinois
|
+$2.15M |
| 2 |
FNY Investment Advisers
New York
|
+$103K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$45.7K |
| 4 |
Sentinus LLC
Oak Brook,
Illinois
|
+$16.1K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$9.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$15.2K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.18K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$898 |
INTS Hedge Fund Activity: Q2 2026 in Review
16 of the 8,381 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q2 2026, worth a combined $2.76M — up 160% from $1.06M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new INTS positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Kingsbury Capital Investment Advisors, adding an estimated $2.15M. The largest seller was Geode Capital Management, cutting an estimated $15.2K.
- 16 institutional investors held Intensity Therapeutics (INTS) as of Q2 2026, up from 14 in Q1 2026.
- Funds reported $2.76M of Intensity Therapeutics stock for Q2 2026, up 160% quarter-over-quarter.
- 3 funds opened new Intensity Therapeutics positions in Q2 2026 and 1 closed out, a net change of +2 holders.
- The largest Intensity Therapeutics buyer in Q2 2026 was Kingsbury Capital Investment Advisors, an estimated $2.15M added.
- The largest Intensity Therapeutics seller in Q2 2026 was Geode Capital Management, an estimated $15.2K sold.
Based on aggregated 13F filings for Q2 2026.